US HB8641 | 2021-2022 | 117th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 3-1)
Status: Introduced on August 2 2022 - 25% progression, died in committee
Action: 2022-08-02 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on August 2 2022 - 25% progression, died in committee
Action: 2022-08-02 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic for the development of orphan drugs, and for other purposes.
Title
Orphan Drug COVID–19 Mitigation Act of 2022
Sponsors
Rep. Josh Gottheimer [D-NJ] | Rep. Don Bacon [R-NE] | Rep. Madeleine Dean [D-PA] | Rep. Kurt Schrader [D-OR] |
History
Date | Chamber | Action |
---|---|---|
2022-08-02 | House | Referred to the House Committee on Energy and Commerce. |
2022-08-02 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/117th-congress/house-bill/8641/all-info |
Text | https://www.congress.gov/117/bills/hr8641/BILLS-117hr8641ih.pdf |